Le Lézard
Classified in: Health, Covid-19 virus
Subjects: STP, MAT

Brad Lamm, CIP President & Founder On: Decriminalization of Drug Possession in Oregon


LOS ANGELES, Nov. 13, 2020 /PRNewswire/ -- Brad Lamm, CIP President & Founder at Breathe Life Healing Centers, discusses how legalizing the possession of hard drugs may affect the patterns of addiction and subsequent treatment of addicts across the state. Addiction and relapse have been on the rise during the COVID-19 pandemic due to compounding stressors, and opening the gateway for treatment rather than incarceration might have a positive lasting effect on the lives of addicts. 

Brad Lamm is a publicly known and well-respected interventionist that has worked tirelessly to drive awareness for support and solutions for families and those suffering with addiction and eating disorders. As an advocate for total health and wellbeing in recovery, he discusses the lasting impact the decriminalization of the possession of hard drugs in the state of Oregon can have. 

Brad Lamm, CIP is an author, speaker, educator, and interventionist. He has been a regular on Oprah, Dr. Oz, Nancy Grace and others. Brad is eager to discuss the lasting impact of this new legislation on the lives of addicts and their families.


Media Contact:
Ethan Ralphs
Phone: (818) 624-0713
Email: [email protected]

Related Images

brad-lamm-cip.jpeg
Brad Lamm, CIP

 

SOURCE Breathe Life Healing Centers


These press releases may also interest you

at 17:23
Emmy-winning actor and St. Louis native Jon Hamm took the stage Saturday, May 18, to offer words of wisdom to the newest graduates of Saint Louis University (SLU) during the University's spring commencement in St. Louis. ...

at 15:09
Nearly 900 undergraduates of the Class of 2024 celebrated their send-off from Bentley University in a very different way than their 2020 arrival amid the COVID-19 pandemic. The 105th undergraduate commencement ceremony was marked by maskless smiles,...

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

at 07:05
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...

17 mai 2024
Federal, provincial and territorial (FPT) ministers responsible for culture and heritage held their annual meeting in Whitehorse, Yukon, on May 15?17, 2024, to discuss priority topics, share information and exchange best practices on current issues...

17 mai 2024
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class Period") of the important June 11, 2024 lead...



News published on and distributed by: